MALCOLM BRENNER to Killer Cells, Natural
This is a "connection" page, showing publications MALCOLM BRENNER has written about Killer Cells, Natural.
Connection Strength
1.214
-
Cellular therapy for cancer: let there be light. Tissue Antigens. 2012 Jan; 79(1):1-3.
Score: 0.333
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.091
-
Homeostatic action of interleukin-4 on endogenous and recombinant interleukin-2-induced activated killer cell function. Blood. 1991 Mar 15; 77(6):1283-9.
Score: 0.079
-
Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
Score: 0.069
-
Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis. Br J Haematol. 1988 Sep; 70(1):37-41.
Score: 0.066
-
Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation. Br J Haematol. 1987 Nov; 67(3):273-9.
Score: 0.062
-
T-cell therapy after hematopoietic stem cell transplantation. Curr Opin Hematol. 2007 Nov; 14(6):616-24.
Score: 0.062
-
Human large granular lymphocytes induce immunoglobulin synthesis after bone marrow transplantation. Eur J Immunol. 1987 Jan; 17(1):43-7.
Score: 0.059
-
The contribution of large granular lymphocytes to B cell activation and differentiation after T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1986 Sep; 42(3):257-61.
Score: 0.057
-
CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
Score: 0.057
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.045
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.038
-
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
Score: 0.033
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.030
-
Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
Score: 0.020
-
Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74.
Score: 0.018
-
Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
Score: 0.018
-
In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation. J Immunol. 1988 May 15; 140(10):3461-6.
Score: 0.016
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.015
-
Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol. 1986 Mar; 62(3):413-20.
Score: 0.014
-
Human clones with natural killer function can activate B cells and secrete B cell differentiation factors. Eur J Immunol. 1985 Jun; 15(6):606-10.
Score: 0.013
-
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
Score: 0.011
-
Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
Score: 0.007